Results
Cohance Lifesciences Q2 Revenue Down 14.2% YoY
Board approved Q2 FY27 unaudited standalone and consolidated financial results showing a 14.2% YoY revenue decline to ₹476.65 Cr.
Appointed Dr. Kuber Jagdale as Chief Technical Officer & Executive Dir
